Table 1. Clinical characteristics and oncological therapies.
| Variable | N | % | % without missing values |
|---|---|---|---|
| Tumor type | |||
| Astrocytoma II | 62 | 7.7 | 7.7 |
| Astrocytoma III | 67 | 8.3 | 8.4 |
| Oligodendroglioma II | 51 | 6.3 | 6.4 |
| Oligodendroglioma III | 34 | 4.2 | 4.2 |
| Oligoastrocytoma II | 40 | 5.0 | 5.0 |
| Oligoastrocytoma III | 52 | 6.4 | 6.5 |
| Glioblastoma multiforme | 268 | 33.1 | 33.5 |
| Metastasis | 88 | 10.9 | 11.0 |
| Other | 139 | 17.2 | 17.3 |
| Missing | 7 | 0.9 | ---- |
| Tumor site | |||
| Frontal | 284 | 35.1 | |
| Temporal | 147 | 18.2 | |
| Parietal | 85 | 10.5 | |
| Occipital | 14 | 1.7 | |
| Insula | 11 | 1.4 | |
| Multicentric | 267 | 32.9 | |
| Seizure type | |||
| Simple partial | 255 | 31.6 | 33.3 |
| Complex partial | 168 | 20.8 | 21.9 |
| Simple partial with secondary generalization | 110 | 13.6 | 14.4 |
| Complex partial with secondary generalization | 82 | 10.1 | 10.2 |
| Simple and complex partial | 19 | 2.4 | 2.5 |
| Generalized tonic-clonic | 132 | 16.3 | 17.2 |
| Missing | 42 | 5.2 | ---- |
| Status epilepticus | |||
| Convulsive | 8 | 1.0 | |
| Non convulsive | 24 | 3.0 | |
| None | 776 | 96.0 | |
| Seizure timing | |||
| Before surgery | 491 | 60.8 | 75.5 |
| After surgery | 152 | 18.8 | 23.4 |
| Before and after surgery | 7 | 0.9 | 1.1 |
| Missing | 158 | 19.6 | ---- |
| Surgery | |||
| Biopsy | 44 | 6.0 | |
| Gross total resection (> 90%) | 470 | 64.2 | |
| Partial resection (< 90%) | 214 | 29.2 | |
| None | 4 | 0.5 | |
| Chemotherapy | |||
| Temozolomide | 388 | 80.3 | |
| Fotemustine | 9 | 1.1 | |
| Bevacizumab | 1 | 0.2 | |
| PCV | 10 | 2.1 | |
| Gliadel | 7 | 1.4 | |
| Other | 50 | 10.3 | |
| None | 18 | 3.7 | |
| Radiotherapy | |||
| Whole brain RT | 88 | 17.3 | |
| IMRT | 38 | 7.5 | |
| Conformational RT | 314 | 61.8 | |
| Stereotaxic | 12 | 2.4 | |
| Radiosurgery | 12 | 2.4 | |
| None | 44 | 8.7 |
AED = Antiepileptic drugs; PCV = Procarbazine, CCNU, and Vincristine; RT = Radiotherapy; IMRT = intensity-modulated radiation therapy.